Inventor profile of:

David Keith Lyon

City:

Bend, Oregon

Country:

United States

Published Applications:

21

Last publication date:

2019-01-17

Top Assignees for applications by David Keith Lyon

The entities that hold a legal rights for patent applications filed by inventor Lyon David Keith:

Recent patent applications by Lyon David Keith

David Keith Lyon from Bend, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2019-01-17
US20190015431A1
Human necessities

Compositions and methods for the treatment of neurodegenerative and other diseases

#2 | 2017-06-15
US20170165279A1
Human necessities

Compositions and methods for the treatment of neurodegenerative and other diseases

#3 | 2017-03-23
US20170079991A1
Human necessities

Compositions and methods for the treatment of neurodegenerative and other diseases

#4 | 2017-03-23
US20170079990A1
Human necessities

Compositions and methods for the treatment of neurodegenerative and other diseases

#5 | 2014-08-07
US20140221321A1
Human necessities

Compositions and methods for the treatment of neurodegenerative and other diseases

#6 | 2012-10-18
US20120264833A1
Chemistry; metallurgy

Pharmaceutical compositions with enhanced performance

#7 | 2011-02-03
US20110027372A1
Human necessities

MULTIPARTICULATES COMPRISING LOW-SOLUBILITY DRUGS AND CARRIERS THAT RESULT IN RAPID DRUG RELEASE

#8 | 2011-01-06
US20110002989A1
Human necessities

METHODS, DOSAGE FORMS AND KITS FOR ADMINISTERING ZIPRASIDONE WITHOUT FOOD

#9 | 2010-02-04
US20100029667A1
Human necessities

Spray dried formulation

#10 | 2010-02-04
US20100028440A1
Human necessities

Drying of drug-containing particles

#11 | 2010-01-07
US20100003331A1
Human necessities

SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE

#12 | 2009-06-04
US20090142401A1
Human necessities

Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release

#13 | 2009-05-07
US20090118328A1
Human necessities

Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase

#14 | 2008-10-23
US20080262107A1
Chemistry; metallurgy

Pharmaceutical compositions with enhanced performance

#15 | 2008-03-27
US20080075784A1
Human necessities

Taste Making Formulation Comprising The Drug In A Dissolution-Retarded Form And/Or Cyclodextrin In A Dissolution-Enhanced Form

#16 | 2008-01-17
US20080015343A1
Human necessities

AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS

#17 | 2007-08-16
US20070190129A1
Human necessities

Sustained release dosage forms of ziprasidone

#18 | 2006-02-23
US20060039988A1
Human necessities

Azithromycin dosage forms with reduced side effects

#19 | 2006-02-09
US20060029677A1
Human necessities

Azithromycin dosage forms with reduced side effects

#20 | 2005-06-16
US20050129772A1
Chemistry; metallurgy

Compositions comprising an HIV protease inhibitor

#21 | 2005-06-09
US20050123627A1
Human necessities

Azithromycin dosage forms with reduced side effects

InventorID:

864021 ⎘